Accentia Announces That Biovest Has Closed an $8.5M Financing to Support Unblinding and Data Analysis of Fast Tracked Pivotal Phase 3 Study of BiovaxID for Non-Hodgkin's Lymphoma with Public Release of Results Anticipated by April 2008.

Extract

---

Accentia Announces That Biovest Has Closed an $8.5M Financing to Support Unblinding and Data Analysis of Fast Tracked Pivotal Phase 3 Study of BiovaxID for Non-Hodgkin's Lymphoma with Public Release of Results Anticipated by April 2008.

An Independent Clinical Study Previously Has Demonstrated 100% of Responding Patients Achieving and Sustaining Significant Disease Free Survival Benefit Measured in Terms of Years

TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announced today that its majority owned subsidiary, Biovest International, Inc. (OTCBB:BVTI) ("Biovest"), has secured an $8.5M debt financing from two institutional investors. The proceeds from the loan will be used in part to finance the analysis of unblinded data on Biova...

See the full content of this document

---